Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.
Tiffany MachAmy QiNathaniel BouganimEmilie TrinhPublished in: Canadian journal of kidney health and disease (2022)
This case report and literature review acknowledges the importance of using alternative methods of assessing kidney function when patients are undergoing targeted cancer therapies known to affect tubular creatinine secretion, which include cyclin-dependent kinase 4/6 inhibitors, poly(adenosine diphosphate-ribose) polymerase inhibitors, tyrosine kinase inhibitors, and mesenchymal-epithelial transition inhibitors. The use of non-creatinine-based markers of glomerular filtration rate (GFR), such as cystatin C and nuclear renal scans, will allow for more accurate estimation of kidney function in the appropriate setting, thus avoiding invasive diagnostic tests and unnecessary adjustments of treatment plans. However, certain targeted cancer therapies have also been proven to cause true kidney injury; therefore, physicians must still maintain a high degree of suspicion and consider invasive investigations and/or cessation or reduction of treatments when alternative measurements of kidney function do not suggest an underestimation of GFR via serum creatinine.
Keyphrases
- papillary thyroid
- uric acid
- squamous cell
- cancer therapy
- end stage renal disease
- chronic kidney disease
- computed tomography
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- metabolic syndrome
- magnetic resonance imaging
- young adults
- peritoneal dialysis
- magnetic resonance
- mass spectrometry
- signaling pathway
- high glucose
- protein kinase
- chronic myeloid leukemia